Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 432 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mitochondrial Diseases Clear all
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 14, 2026, 2:48 PM EDT
Completed No phase listed Observational

Mitochondrial Video Assessment Source Material Study

NCT06180421
View directory record Official record
Conditions
PolG, Primary Mitochondrial Myopathy
Interventions
Not listed
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kingston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 14, 2026, 2:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kaempferol Absorption and Pharmacokinetics Evaluation

NCT07322406
View directory record Official record
Conditions
No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions
Kaempferol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 14, 2026, 2:48 PM EDT
Not yet recruiting Not applicable Interventional

Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.

NCT07556939
View directory record Official record
Conditions
Reperfusion Injury, Post Cardiac Arrest Brain Injury
Interventions
LUTICIA - Light Utilization COX-Inhibitory Device)
Device
Lead sponsor
Mitovation, Inc
Industry
Eligibility
48 Hours to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 14, 2026, 2:48 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

O2 Transport and Utilization in Health and Lung Disease

NCT04014712
View directory record Official record
Conditions
COPD, Tetrahydrobiopterin Deficiency, Oxidative Stress
Interventions
Tetrahydrobiopterin, Placebo oral tablet
Drug
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Early Phase 1 Interventional

Rosuvastatin (Crestor) in Friedreich Ataxia

NCT02705547
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Rosuvastatin
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

NCT05285540
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
DT-216, DT-216 matching Placebo
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 14, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

NCT04519567
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 14, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

NCT01681368
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Birinapant (TL32711)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

NCT01386970
View directory record Official record
Conditions
HIV
Interventions
zidovudine 300mg and lamivudine 150mg as Combivir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 14, 2026, 2:48 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients

NCT00036478
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 14, 2026, 2:48 PM EDT
Recruiting Not applicable Interventional

Autologous Mitochondrial Transplant for Cerebral Ischemia

NCT04998357
View directory record Official record
Conditions
Cerebral Ischemia
Interventions
Endovascular autologous mitochondrial transplantation
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 14, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects

NCT03565328
View directory record Official record
Conditions
Heart Failure
Interventions
Nicotinamide Riboside
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mitochondrial Dysfunction in Diabetes

NCT01724502
View directory record Official record
Conditions
Diabetes, Obese
Interventions
Exercise and muscle biopsies
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

NCT01816165
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 59 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

NCT02352896
View directory record Official record
Conditions
Leigh Syndrome
Interventions
EPI-743
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Stanford University, California • Akron, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans

NCT02892331
View directory record Official record
Conditions
Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions
Moderate intensity exercise training (MOD-INT), High Intensity exercise training (HI-INT)
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 14, 2026, 2:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Insulin and Muscle Fat Metabolism

NCT04759872
View directory record Official record
Conditions
Overweight and Obesity, Insulin Resistance, Metabolic Disease, Mitochondrial Metabolism, Sedentary Lifestyle
Interventions
Hyperinsulinemic-euglycemic Clamp
Other
Lead sponsor
Oregon State University
Other
Eligibility
30 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 14, 2026, 2:48 PM EDT
No Longer Available No phase listed Expanded access

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

NCT02300753
View directory record Official record
Conditions
Leber's Hereditary Optic Neuropathy
Interventions
EPI-743
Drug
Lead sponsor
Edison Pharmaceuticals Inc
Industry
Eligibility
8 Years to 65 Years
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 14, 2026, 2:48 PM EDT
Active, not recruiting Phase 2 Interventional

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

NCT02171104
View directory record Official record
Conditions
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Phase 1Phase 2 Interventional

Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).

NCT06051448
View directory record Official record
Conditions
Mitochondrial Diseases, Mitochondrial Myopathies, Mitochondrial Encephalomyopathies, MELAS, MERRF
Interventions
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN)
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 14, 2026, 2:48 PM EDT
Recruiting Phase 3 Interventional

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

NCT05422534
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
CoQ10, Placebo, HB-HIIT, Observational
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 14, 2026, 2:48 PM EDT
Completed Not applicable Interventional

Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies

NCT01970332
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Revascularization Surgery, Supervised exercise therapy
Procedure · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 14, 2026, 2:48 PM EDT